Cargando…
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus
Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or mul...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810475/ https://www.ncbi.nlm.nih.gov/pubmed/34994811 http://dx.doi.org/10.1007/s00277-021-04746-y |
_version_ | 1784644261229101056 |
---|---|
author | Henze, Larissa Buhl, Christoph Sandherr, Michael Cornely, Oliver A. Heinz, Werner J. Khodamoradi, Yascha Kiderlen, Til Ramon Koehler, Philipp Seidler, Alrun Sprute, Rosanne Schmidt-Hieber, Martin von Lilienfeld-Toal, Marie |
author_facet | Henze, Larissa Buhl, Christoph Sandherr, Michael Cornely, Oliver A. Heinz, Werner J. Khodamoradi, Yascha Kiderlen, Til Ramon Koehler, Philipp Seidler, Alrun Sprute, Rosanne Schmidt-Hieber, Martin von Lilienfeld-Toal, Marie |
author_sort | Henze, Larissa |
collection | PubMed |
description | Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 “Antiviral prophylaxis in patients with solid tumours and haematological malignancies” focusing on herpes simplex virus and varicella zoster virus. |
format | Online Article Text |
id | pubmed-8810475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-88104752022-02-23 Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus Henze, Larissa Buhl, Christoph Sandherr, Michael Cornely, Oliver A. Heinz, Werner J. Khodamoradi, Yascha Kiderlen, Til Ramon Koehler, Philipp Seidler, Alrun Sprute, Rosanne Schmidt-Hieber, Martin von Lilienfeld-Toal, Marie Ann Hematol Original Article Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 “Antiviral prophylaxis in patients with solid tumours and haematological malignancies” focusing on herpes simplex virus and varicella zoster virus. Springer Berlin Heidelberg 2022-01-07 2022 /pmc/articles/PMC8810475/ /pubmed/34994811 http://dx.doi.org/10.1007/s00277-021-04746-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Henze, Larissa Buhl, Christoph Sandherr, Michael Cornely, Oliver A. Heinz, Werner J. Khodamoradi, Yascha Kiderlen, Til Ramon Koehler, Philipp Seidler, Alrun Sprute, Rosanne Schmidt-Hieber, Martin von Lilienfeld-Toal, Marie Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
title | Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
title_full | Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
title_fullStr | Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
title_full_unstemmed | Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
title_short | Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
title_sort | management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the guidelines of the infectious diseases working party (agiho) of the german society for hematology and medical oncology (dgho) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810475/ https://www.ncbi.nlm.nih.gov/pubmed/34994811 http://dx.doi.org/10.1007/s00277-021-04746-y |
work_keys_str_mv | AT henzelarissa managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT buhlchristoph managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT sandherrmichael managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT cornelyolivera managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT heinzwernerj managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT khodamoradiyascha managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT kiderlentilramon managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT koehlerphilipp managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT seidleralrun managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT spruterosanne managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT schmidthiebermartin managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva AT vonlilienfeldtoalmarie managementofherpesvirusreactivationsinpatientswithsolidtumoursandhematologicmalignanciesupdateoftheguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyforhematologyandmedicaloncologydghoonherpessimplexvirustype1herpessimplexvirustype2andva |